5-环己基-1,3,4-噻二唑-2-胺 | 56882-77-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-环己基-1,3,4-噻二唑-2-胺
• 英文名称: 5-cyclohexyl-1,3,4-thiadiazol-2-amine
• 英文别名: 2-amino-5-cyclohexyl-1,3,4-thiadiazole
• CAS: 56882-77-0
• 化学式: C₈H₁₃N₃S
• mdl: MFCD00469715
• 分子量: 183.277
• InChiKey: BLBDGPFJLDEFFL-UHFFFAOYSA-N

物化性质

• 熔点：
  243-245 °C
• 沸点：
  343.8±25.0 °C(Predicted)
• 密度：
  1.231±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 5-Cyclohexyl-1,3,4-Thiadiazol-2-Amine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 183,27 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
5-Cyclohexyl-1,3,4-Thiadiazol-2-Amine
Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
5-Cyclohexyl-1,3,4-Thiadiazol-2-Amine
T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (5-Cyclohexyl-1,3,4-Thiadiazol-2-Amine)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (5-Cyclohexyl-1,3,4-Thiadiazol-2-Amine)
IATA: Toxic solid, organic, n.o.s. (5-Cyclohexyl-1,3,4-Thiadiazol-2-Amine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H301 Toxic if swallowed.
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  5-环己基-1,3,4-噻二唑-2-胺 在 sodium hydroxide 作用下， 以 乙醇 、 水 、 苯 为溶剂， 反应 5.0h， 生成 2-[6-bromo-3-(4-methoxyphenyl)-4-oxoquinazolin-2-yl]sulfanyl-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)acetamide
  参考文献：
  名称：

  Misra; Gupta, European Journal of Medicinal Chemistry, 1982, vol. 17, # 3, p. 216 - 218

  摘要：

  DOI：
• 作为产物：
  描述：

  1-cyclohexylidenethiosemicarbazide 在 iron(III) chloride 作用下， 以 乙醇 为溶剂， 以77%的产率得到5-环己基-1,3,4-噻二唑-2-胺
  参考文献：
  名称：

  Synthesis and evaluation of novel 1,3,4-thiadiazole{ uoroquinolone hybrids as antibacterial, antituberculosis, and anticancer agents

  摘要：

  一系列5-取代-1,3,4-噻二唑基氟喹诺酮衍生物被设计为潜在的抗菌和抗癌药物，采用分子杂交方法。目标化合物16-25是通过将相应的 $N$-（5-取代-1,3,4-噻二唑-2-基）-2-氯乙酰胺与环丙沙星或诺氟沙星反应合成的。合成化合物的纯度和身份通过色谱和光谱技术（NMR、IR、MS等）以及元素分析确定。目标化合物的抗菌、抗结核和抗癌活性针对选定的菌株和癌细胞系进行了评估。化合物20被认为是最活跃的抗菌剂，对大肠杆菌和金黄色葡萄球菌的MIC值分别为4 $\mu $g/mL和2 $\mu $g/mL。在合成的氟喹诺酮衍生物中，化合物19和20被发现具有适度的抗结核活性，每个化合物的MIC值为8 $\mu $g/mL。最强大的衍生物，化合物20与金黄色葡萄球菌和结核分枝杆菌DNA拓扑异构酶酶对接，以可视化化合物的可能构象。此外，目标化合物的抗癌活性在七种不同的癌细胞系上进行了评估。

  DOI：

  10.3906/kim-1710-35

文献信息

• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20150322063A1

  公开（公告）日：2015-11-12

  A compound represented by Formula [1] (in the formula, Z 1 represents N, CH, or the like; X 1 represents NH or the like; R 1 represents a heteroaryl group or the like; each of R 2 , R 3 , and R 4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R 5 represents a heteroaryl group or the like) or salt thereof.

  由式[1]表示的化合物（在该式中，Z表示N、CH或类似物；X表示NH或类似物；R表示杂环烷基或类似物；R2、R3和R4中的每一个表示氢原子、卤原子、烷氧基或类似物；R5表示杂环烷基或类似物）或其盐。
• PhI-Catalyzed Intramolecular Oxidative Coupling Toward Synthesis of 2-Amino-1,3,4-Thiadizoles
  作者：Yingzhi Han、Yadong Sun、Ablimit Abdukader、Bifu Liu、Duozhi Wang

  DOI：10.1007/s10562-018-2541-y

  日期：2018.11

  derivatives via intramolecular oxidative coupling of thiosemicarbazide, using the in situ generated hypervalent iodine(III) reagents is developed. The protocol can be carried out smoothly and provides a variety of thiadiazole derivatives in moderate to excellent yields.Graphical AbstractA highly efficient method for the synthesis of thiadiazole derivatives via PhI-catalyzed intramolecular oxidative coupling

  摘要 开发了一种利用原位生成的高价碘（III）试剂，通过氨基硫脲的分子内氧化偶联合成噻二唑衍生物的高效方法。该协议可以顺利进行，并以中等至优异的收率提供各种噻二唑衍生物。图形摘要一种高效的合成噻二唑衍生物的方法通过 PhI 催化分子内氧化偶联氨基硫脲。
• N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification
  作者：Wenjie Xue、Xueyao Li、Guixing Ma、Hongmin Zhang、Ya Chen、Johannes Kirchmair、Jie Xia、Song Wu

  DOI：10.1016/j.ejmech.2019.112022

  日期：2020.2

  new class of antibacterial agents, as one of its derivatives was identified as an antibacterial agent against S. aureus. However, no potency-directed structural optimization has been performed. In this study, we designed and synthesized 37 derivatives, and evaluated their antibacterial activity against S. aureus ATCC29213, which led to the identification of ten potent antibacterial agents with minimum

  由于发生抗生素抗性，细菌感染性疾病已成为对公共健康的严重威胁。为了克服抗生素抗性，迫切需要新型抗生素。N-噻二唑-4-羟基-2-喹诺酮-3-羧酰胺是一类潜在的新型抗菌剂，因为其衍生物之一被确定为针对金黄色葡萄球菌的抗菌剂。但是，尚未执行效能导向的结构优化。在这项研究中，我们设计和合成了37种衍生物，并评估了它们对金黄色葡萄球菌ATCC29213的抗菌活性，从而鉴定出十种有效抑菌剂，其最低抑菌浓度（MIC）值均低于1μg/ mL。接下来，我们针对一组抗药性临床分离株进行了细菌生长抑制测定，包括耐甲氧西林的金黄色葡萄球菌，以及对HepG2和HUVEC细胞的细胞毒性测定。一种被测试的化合物，称为1-乙基-4-羟基-2-氧代-N-（5-（噻唑-2-基）-1,3,4-噻二唑-2-基）-1,2-二氢喹啉-与万古霉素相比，3-羧酰胺（g37）对被测菌株的抗菌力（MIC：0.25-1μg/ mL对1-64μg/
• Novel 1,3,4-thiadiazole conjugates derived from protocatechuic acid: Synthesis, antioxidant activity, and computational and electrochemical studies
  作者：Katarina Jakovljević、Milan D. Joksović、Bruno Botta、Ljiljana S. Jovanović、Edina Avdović、Zoran Marković、Vladimir Mihailović、Marijana Andrić、Snežana Trifunović、Violeta Marković

  DOI：10.1016/j.crci.2019.06.001

  日期：2019.8

  Abstract A series of 15 novel 1,3,4-thiadiazole amide derivatives containing a protocatechuic acid moiety were synthesized and structurally characterized. In addition, the corresponding imino (4) and amino (5) analogues of a phenyl-substituted 1,3,4-thiadiazole amide derivative 3a were prepared to compare the effects of the structural changes on the radical-scavenging activity. The obtained compounds

  摘要 合成了一系列含有原儿茶酸部分的 15 种新型 1,3,4-噻二唑酰胺衍生物并对其进行了结构表征。此外，还制备了苯基取代的 1,3,4-噻二唑酰胺衍生物 3a 的相应亚氨基 (4) 和氨基 (5) 类似物，以比较结构变化对自由基清除活性的影响。通过 2,2-二苯基-1-苦基肼 (DPPH) 和 2,2'-叠氮基-双 (3-乙基苯并噻唑啉-6-磺酸) (ABTS) 测定法检查所得化合物的抗氧化潜力。此外，通过密度泛函理论 (DFT) 和循环伏安法实验研究了选定的化合物。与参考抗氧化剂抗坏血酸和去甲二氢愈创木酸 (NDGA) 相比，测试的化合物显示出清除 DPPH 自由基和 ABTS 自由基阳离子的高潜力。根据计算的热力学参数，可以得出结论，顺序质子丢失电子转移（SPLET）机制代表了极性溶剂中最可能的 DPPH 自由基清除活性的反应路径。另一方面，在 ABTS 自由基阳离子的情况下，单电子转移和质子转移
• Thiadiazole derivatives active on the central nervous system and
  申请人：Sanofi

  公开号：US04596802A1

  公开（公告）日：1986-06-24

  The invention relates to thiadiazole derivatives corresponding to the formula: ##STR1## in which R represents: a linear or branched alkyl group having from 1 to 5 carbon atoms; a cycloalkyl group having 5 or 6 carbon atoms; a phenyl group optionally substituted by 1 or 2 halogen atoms, preferably chlorine, by 1 or 2 lower alkyl or lower alkoxy groups, by 1 or 2 hydroxyl groups or by a nitro or trifluoromethyl group; a biphenylyl group; or an alpha-naphthyl group; and the pharmaceutically acceptable salts of the said derivatives. It also relates to a process for the preparation of the said derivatives and the pharmaceutical compositions in which they are present. The said derivatives act on the central nervous system.

  该发明涉及与以下结构对应的噻二唑衍生物：##STR1## 其中R代表：具有1至5个碳原子的直链或支链烷基基团；具有5或6个碳原子的环烷基基团；一苯基基团，可以被1或2个卤原子（优选氯）、1或2个较低的烷基或较低的烷氧基团、1或2个羟基或一个硝基或三氟甲基基团取代；一个联苯基团；或一个α-萘基团；以及所述衍生物的药用盐。还涉及制备所述衍生物的方法以及它们所含的药物组合物。所述衍生物对中枢神经系统起作用。